Mesoblast Limited, an innovative leader in regenerative medicine, is headquartered in Australia and operates extensively across North America, Europe, and Asia. Founded in 2004, the company has made significant strides in developing advanced cell-based therapies, particularly in the fields of orthopaedics, cardiovascular diseases, and inflammatory conditions. Mesoblast's core products, including its proprietary allogeneic cell therapy platforms, are designed to address unmet medical needs with unique mechanisms of action that promote healing and tissue regeneration. The company has achieved notable milestones, including successful clinical trials and partnerships that enhance its market position in the biotechnology sector. With a commitment to transforming patient care, Mesoblast continues to be at the forefront of innovation in regenerative medicine.
How does Mesoblast Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Mesoblast Limited's score of 16 is lower than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mesoblast Limited, headquartered in Australia, currently does not report any specific carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the company has not established any documented reduction targets or climate pledges. As of now, Mesoblast Limited does not inherit emissions data from any parent or related organizations, indicating that their climate commitments and emissions reporting are independent. Without specific emissions data or reduction initiatives, it is unclear how the company is addressing climate change within its operations. In the absence of concrete figures or commitments, stakeholders may look forward to future disclosures that could outline Mesoblast's approach to sustainability and carbon management.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mesoblast Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.